Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687304 | 0.92 | PIK3CA (0.45) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL1623280 | 0.91 | PIK3CA (0.49) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL14886173 | 0.88 | PIK3CA (0.47) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL1687121 | 0.86 | PIK3CA (0.49) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL7711390 | 0.84 | PIK3CA (0.39) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1623257 | 0.83 | PIK3CA (0.49) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL1284297 | 0.81 | PIK3CA (0.45) | PIK3CAPIK3R1SIRT2SIRT1SIRT3 | |
| SCHEMBL1285079 | 0.78 | PIK3CA (0.49) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1283941 | 0.76 | HDAC1 (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL7711385 | 0.76 | PIK3CA (0.39) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885SIRT2 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.